Long-term results of weekly paclitaxel carboplatin induction therapy: An effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer

Abstract Background Weekly paclitaxel/cisplatin is effective in platinum-resistant epithelial ovarian cancer (EOC). To reduce toxicity, paclitaxel/cisplatin was replaced by paclitaxel/carboplatin. Patients and methods Patients with progressive EOC after prior 3-weekly paclitaxel/carboplatin were tre...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2013-04, Vol.49 (6), p.1254-1263
Main Authors: van der Burg, M.E.L, Vergote, I, Onstenk, W, Boere, I.A, Leunen, K, van Montfort, C.A.G.M, van Doorn, H.C
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Carboplatin - administration & dosage
Carboplatin - adverse effects
Disease-Free Survival
Dose-dense therapy
Drug Administration Schedule
Drug Resistance, Neoplasm - drug effects
Female
Hematology, Oncology and Palliative Medicine
Humans
Induction Chemotherapy - methods
Medical sciences
Middle Aged
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Nausea - chemically induced
Neoplasm Grading
Neutropenia - chemically induced
Ovarian cancer
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - pathology
Paclitaxel - administration & dosage
Paclitaxel - adverse effects
Paclitaxel/carboplatin
Pharmacology. Drug treatments
Platinum-resistant
Platinum-sensitive
Recurrent ovarian cancer
Thrombocytopenia - chemically induced
Time Factors
Treatment Outcome
Tumors
Vomiting - chemically induced
Weekly-regimen
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Weekly paclitaxel/cisplatin is effective in platinum-resistant epithelial ovarian cancer (EOC). To reduce toxicity, paclitaxel/cisplatin was replaced by paclitaxel/carboplatin. Patients and methods Patients with progressive EOC after prior 3-weekly paclitaxel/carboplatin were treated with six cycles weekly paclitaxel 90 mg/m2 and carboplatin area under the curve (AUC) 4 mg/ml/min, followed by six cycles 3-weekly paclitaxel/carboplatin. End-points were progression free survival (PFS), overall survival (OS), response rate (RR) and toxicity. Results Median progression free interval after last platinum was 9 (0–81) months in 108 patients; 43 were platinum-resistant, of whom 13 started weekly paclitaxel/carboplatin
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2012.11.027